45MO Sotorasib in Combination with Panitumumab in Refractory KRAS G12C-Mutated Colorectal Cancer: Safety and Efficacy for Phase Ib Full Expansion Cohort
Open accessIntegrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a recent phase 1b study, sotorasib plus panitumumab produced a confirmed response of 30% in pretreated KRAS G12C colorectal cancer patients, compared with 10% for sotorasib monotherapy.
“Early clinical data support this hypothesis, and in a recent phase 1b study of sotorasib in combination with the EGFR-targeting monoclonal antibody panitumumab, a confirmed response of 30% was reported in pretreated patients who had colorectal cancer with a KRAS G12C mutation,32 as compared with 10% for sotorasib monotherapy.30”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated <i>KRAS</i> G12C (2023) · cites this paper as [32]
In pretreated colorectal cancer patients with KRASG12C mutation, sotorasib plus panitumumab achieved an objective response rate of 30% compared to 10% for sotorasib monotherapy.
“In a recent phase Ib study involving sotorasib in combination with the EGFR-targeted monoclonal antibody panitumumab, an objective response rate of 30% was reported in pretreated patients with colorectal cancer harboring a KRASG12C mutation, compared to 10% for sotorasib monotherapy [22,34].”
From KRAS, a New Target for Precision Medicine in Colorectal Cancer? (2024) · cites this paper as [34]
Combining an EGFR-directed antibody with a KRASG12C inhibitor is a clinically effective strategy to mitigate EGFR reactivation.
“The combination of an EGFR-directed antibody with a KRASG12C inhibitor is a clinically effective strategy to mitigate EGFR reactivation (Table 2).”
From KRAS, a New Target for Precision Medicine in Colorectal Cancer? (2024) · cites this paper as [34]
Cites
Still being checked.
Cited by
Sorted by citations
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C Mutation
Sacher, A., LoRusso, P., Patel, M. R., Miller, W. H., Garralda, E., Forster, M. D., Santoro, A., Falcon, A., Kim, T. W., Paz-Ares, L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303810 · Cited by 328 · see citing works
Gonzalez, N. S., Salvà, F., Ros, J., Baraibar, I., Rodríguez-Castells, M., García, A., Alcaráz, A., Vega, S., Bueno, S., Tabernero, J. M., et al. (2023) · Cancers · doi:10.3390/cancers15164020 · Cited by 64 · see citing works
Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
Gonzalez, N. S., Ros, J., Baraibar, I., Salvà, F., Rodríguez-Castells, M., Alcaráz, A., García, A., Tabernero, J. M., & Élez, E. (2024) · Cancers · doi:10.3390/cancers16020412 · Cited by 47 · see citing works
Sotorasib Is a Pan- RAS G12C Inhibitor Capable of Driving Clinical Response in NRAS G12C Cancers
Rubinson, D. A., Tanaka, N., de la Cruz, F. F., Kapner, K. S., Rosenthal, M. H., Norden, B. L., Barnes, H., Ehnstrom, S., Morales-Giron, A. A., Brais, L. K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1138 · Cited by 46 · see citing works
From bench to bedside: current development and emerging trend of KRAS-targeted therapy
Chen, Y., Liu, Q.-P., Xie, H., & Ding, J. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01194-4 · Cited by 44 · see citing works
Baranyi, M., Molnár, E., Hegedüs, L., Gábriel, Z., Petenyi, F. G., Bordás, F., Lener, V., Ranđelović, I., Cserepes, M., Tóvári, J., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02586-x · Cited by 35 · see citing works
Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
Bteich, F., Mohammadi, M., Li, T., Bhat, M. A., Sofianidi, A. A., Wei, N., & Kuang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512030 · Cited by 32 · see citing works
Caughey, B. A., & Strickler, J. H. (2023) · Drugs · doi:10.1007/s40265-023-01980-8 · Cited by 14 · see citing works
Self-citationKRAS, a New Target for Precision Medicine in Colorectal Cancer?
Boilève, A., Smolenschi, C., Lambert, A., Boige, V., Delaye, M., Camilleri, G. M., Tarabay, A., Valéry, M., Fuerea, A., Pudlarz, T., et al. (2024) · Cancers · doi:10.3390/cancers16203455 · Cited by 11 · see citing works
Advances and prospects of drug clinical research in colorectal cancer in 2022
Su, D., Liu, C., Cui, J., Tang, J., Ruan, Y., & Zhang, Y. (2023) · Cancer Innovation · doi:10.1002/cai2.62 · Cited by 11 · see citing works
Targeting KRAS in colorectal cancer (Review)
Zhang, M., Wu, D., Tang, C. Y. L., Zhang, L., Zhang, S., Li, W., Li, N., & Yan, X. (2025) · Molecular and Clinical Oncology · doi:10.3892/mco.2025.2873 · Cited by 7 · see citing works
Clinical Actionability of Genes in Gastrointestinal Tumors
Gonzalez, N. S., Patelli, G., & Crisafulli, G. (2025) · Genes · doi:10.3390/genes16101130 · Cited by 7 · see citing works
Precision oncology for KRASG12C-mutant colorectal cancer
Nicolantonio, F. D., & Bardelli, A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00748-z · Cited by 7 · see citing works
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Wu, C., Li, W., Chen, M., Zhang, Q., Xu, T., Ma, Y., Liu, W., Wang, Z., Wang, X., Li, J., et al. (2023) · Holistic Integrative Oncology · doi:10.1007/s44178-023-00032-1 · Cited by 5 · see citing works
García-Román, S., Garzón‐Ibáñez, M., Bertrán-Alamillo, J., Jordana‐Ariza, N., Giménez-Capitán, A. A., García‐Peláez, B., Vives-Usano, M., Codony‐Servat, J., d'Hondt, E., Rosell, R., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101878 · Cited by 4 · see citing works
Moretto, R., Rossini, D., Murgioni, S., Ciracì, P., Nasca, V., Germani, M. M., Calegari, M. A., Vetere, G., Intini, R., Taravella, A., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00329 · Cited by 3 · see citing works
Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance
Luo, X., Zhou, F., Tang, Y., Liu, X., Xiao, R., Gu, M., Bai, J., Jiang, D., Yang, G., You, L., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003776 · Cited by 2 · see citing works
KRAS G12C mutation in metastatic colorectal cancer: a new target
Ibrahim, R., Saleh, K., Chahine, C., Khoury, R., Khalife, N., & Cesne, A. L. (2023) · Future Oncology · doi:10.2217/fon-2023-0223
Espin-Lanz, E., Camargo, N. F., Perez, D., Zabaleta, A., Chaparro, W. H. S., & Padrón, O. L. (2025) · Revista Colombiana de Cirugía · doi:10.30944/20117582.3057
Xiong, S., Luo, D., Zhong, M., Huang, C., Deng, M., He, H., Shan, J., Yuan, T., Liang, J., Fan, Y., et al. (2026) · Materials Advances · doi:10.1039/d6ma00423g
- Authors
- Kuboki, Y., Yaeger, R., Fakih, M., Strickler, J. H., Masuishi, T., Kim, E. J.-H., Bestvina, C. M., Langer, C. J., Krauss, J. C., Puri, S., Cardona, P., Chang, E. K., Tran, Q., & Hong, D. S.
- Affiliations
- National Cancer Center Hospital East (JP)
- Memorial Sloan Kettering Cancer Center (US)
- City Of Hope National Medical Center (US)
- Duke University (US)
- Aichi Cancer Center (JP)
- University of California Davis Medical Center (US)
- University of Chicago (US)
- University of Pennsylvania (US)
- University of Michigan (US)
- University of South Florida (US)
- Amgen (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2022-11
- Volume
- 33
- Pages
- S1445-S1446
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4310753291
- Cited by
- 20
- References
- 0
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 6 · 2023: 9
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- sotorasib, panitumumab, KRAS G12C mutation, metastatic colorectal cancer, KRAS inhibitors, anti-EGFR monoclonal antibody, combination therapy, refractory disease, treatment efficacy and safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
